Pharmaron Beijing Co (HKSE:03759) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03759 Pharmaron Beijing Co Ltd HKSE:03759
93 GF Score
Price HK$23.66
GF Value HK$20.47
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:03759
93GF Score
Pharmaron Beijing Co Ltd HKSE:03759
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of HK$23.66 is trading 15.6% above its estimated GF Value™ of HK$20.47. GuruFocus considers Pharmaron Beijing Co to be Fairly Valued.

Key valuation signals for HKSE:03759:

  • FFO:
  • GF Value™: HK$20.47 vs. price of HK$23.66 (15.6% above fair value)
  • GF Score™: 93/100 with 9 warning signs

No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmaron Beijing Co Business Description

Other Exchanges 17Q1:Germany300759:China
Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
93GF Score

Get the complete analysis for HKSE:03759

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$23.66
Price
HK$20.47
GF Value